My Healthcare News & Research — March 24, 2026

Table of Contents

FDA to Reopen the DSHEA "Innovation Door" — Historic Public Meeting March 27

In what many industry leaders are calling the most significant regulatory development for dietary supplements since the introduction of Good Manufacturing Practices (GMPs), the U.S. Food and Drug Administration has announced a landmark public meeting scheduled for March 27, 2026, titled "Exploring the Scope of Dietary Supplement Ingredients."

The meeting will revisit the foundational definitions established by the Dietary Supplement Health and Education Act (DSHEA) of 1994 — the 32-year-old law that governs what qualifies as a dietary ingredient. Specifically, the FDA will examine the meaning of the phrase "dietary substance for use by man to supplement the diet by increasing the total dietary intake" and whether it accommodates modern innovations in ingredient science.

What's on the Agenda

The meeting will feature presentations covering three critical areas:

The meeting will be held from 9:00 a.m. to 3:00 p.m. ET at the FDA's Human Foods Program location in College Park, MD (Wiley Auditorium, 5001 Campus Drive), with virtual attendance available. A 30-day public comment period runs through April 27, 2026 (docket number FDA-2026-N-2047).

Why This Matters

For decades, the supplement industry has argued that DSHEA's rigid definitions have blocked innovation, preventing promising ingredients like certain peptide therapies (BPC-157), novel probiotic strains, and bioactive compounds from being legally marketed as dietary supplements. The FDA's willingness to revisit these definitions signals a potential paradigm shift that could open the floodgates for an entirely new class of health products.

However, consumer advocacy groups warn that broadening the definition could allow insufficiently studied substances to reach the market with minimal safety oversight. The outcome of this meeting and subsequent rulemaking could reshape the entire $64 billion supplement industry.

Sources: FDA — Public Meeting: Exploring the Scope of Dietary Supplement Ingredients | NutraIngredients — Is FDA Opening the Long-Shut DSHEA Innovation Door? | NutraIngredients — Could 2026 Be the Biggest Year for Dietary Supplements?

43-Year Harvard Study: Daily Coffee and Tea Linked to 18% Lower Dementia Risk

A major prospective study published in JAMA in February 2026 has found that moderate daily consumption of caffeinated coffee or tea is associated with significantly lower dementia risk and better cognitive performance over time. The research, led by investigators from Mass General Brigham, the Harvard T.H. Chan School of Public Health, and the Broad Institute of MIT and Harvard, analyzed data spanning an extraordinary 43 years of follow-up.

Key Findings

The study followed 131,821 participants from the Nurses' Health Study and Health Professionals Follow-Up Study, of whom 11,033 developed dementia during the observation period. The results were striking:

Implications for Brain Health

The findings add to a growing body of evidence that caffeine has direct neuroprotective properties, potentially through its ability to block adenosine receptors, reduce neuroinflammation, and modulate amyloid-beta accumulation — a hallmark of Alzheimer's disease. The 43-year follow-up period makes this one of the longest prospective studies ever conducted on dietary factors and cognitive decline.

The researchers emphasized that these are observational findings and cannot establish causation, but the consistency of results across both sexes, multiple beverages, and decades of follow-up strengthens the evidence for a genuine protective association.

Sources: JAMA — Coffee and Tea Intake, Dementia Risk, and Cognitive Function | Harvard Gazette — Drinking 2-3 Cups of Coffee a Day Tied to Lower Dementia Risk | ScienceDaily — Your Daily Coffee May Be Protecting Your Brain, 43-Year Study Finds

Naturopathic Healthcare Use Nearly Doubles in Two Decades

According to data from the National Health Interview Survey (NHIS), the percentage of Americans using complementary and alternative healthcare services has risen dramatically, from 19.2% in 2002 to 36.7% in 2022 — representing approximately 122 million people receiving these services in 2022 alone.

The umbrella of complementary and alternative medicine (CAM) includes yoga, meditation, massage therapy, chiropractic care, acupuncture, naturopathy, herbal medicine, and guided imagery. Within this broad category, naturopathic medicine specifically has quadrupled, rising from 0.3% to 1.3% of U.S. adults — approximately 4.4 million Americans now consulting naturopathic doctors.

What's Driving the Surge

Several converging factors are fueling the shift toward natural healthcare:

The trend is particularly notable in states that license naturopathic doctors (currently 29 states plus DC), where NDs can serve as primary care providers. In Kansas City and other metro areas, patients who feel failed by conventional medicine are increasingly turning to naturopathic doctors as a first-line option rather than a last resort.

Sources: Central Maine — More Americans Are Turning to Naturopathic Healthcare | NIH — Significant Rise in Use of Complementary Health Approaches | AANP — The Data Speaks: Naturopathic Doctors Are Thriving Professionally

Global Herbal Supplement Market Surges Past $64 Billion

The global herbal supplements market is projected to exceed $64 billion by 2026, growing at a compound annual growth rate (CAGR) of over 11%. Within this booming market, the adaptogens segment alone has reached an estimated $13.9 billion, growing at 10.1% CAGR — making it one of the fastest-growing subsectors in the entire supplement industry.

What's Driving the Boom

Trending Ingredients for 2026

Industry analysts identify magnesium glycinate as the #1 trending supplement (+33.6% year-over-year search growth), followed by berberine (dubbed "nature's Ozempic" with +49% growth), sea moss and shilajit (both viral on TikTok), and medicinal mushrooms including lion's mane, reishi, chaga, and turkey tail. The gut-brain axis and longevity/anti-aging categories are seeing explosive consumer interest.

Sources: Herbal Supplements Market — Why the Market is Booming in 2026 | Precedence Research — Adaptogens Market Size to Surpass $21.92 Billion by 2034 | SupplySide — Industry Vet Identifies Top Supplement Trends for 2026

Melatonin for Children: Scientists Raise Red Flags as Use Skyrockets

While melatonin has become the go-to sleep aid for millions of American children, a systematic review published in JAMA Network Open in early 2026 warns that the enthusiasm may be dangerously outpacing the evidence. The review found strong support for melatonin's short-term effectiveness in children with neurodevelopmental disorders such as autism and ADHD, but sparse and inconsistent evidence for typically developing children with insomnia.

The Scale of the Problem

Melatonin is now the leading cause of unsupervised medication exposure in emergency departments for children aged 0–6 years. Researchers attribute this to gummy formulations that resemble candy and improper storage at home. The rate of pediatric melatonin ingestions reported to poison control centers has increased by over 500% in the past decade.

Product Quality Concerns

Adding to safety concerns, independent laboratory testing has found alarming variability in melatonin concentrations in over-the-counter products. Studies show actual melatonin content in supplements ranges from −83% to +478% of the labeled dose. This means a product claiming to contain 1 mg of melatonin could contain anywhere from 0.17 mg to 5.78 mg — a variation that is especially dangerous for young children whose bodies are highly sensitive to hormonal inputs.

Unresolved Long-Term Questions

Scientists emphasize that long-term safety data are particularly lacking, with unresolved questions about melatonin's potential effects on:

Pediatric sleep specialists recommend that melatonin should only be used in children after behavioral sleep interventions have been tried, at the lowest effective dose, and ideally under medical supervision rather than as a first-line over-the-counter remedy.

Sources: JAMA Network Open — Melatonin Use in Young Children: A Systematic Review | ScienceDaily — Millions of Kids Take Melatonin but Doctors Are Raising Red Flags | EurekAlert — Why Experts Urge Caution on Melatonin Use in Children

FDA May Relax Dietary Supplement Warning Label Rules

The FDA is considering loosening the regulation that requires the repeated display of the disclaimer "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease" on dietary supplement packaging. Under the proposed change, companies would only need to display the mandatory FDA disclosure once on the label rather than next to each individual health claim.

The agency argues that the change would reduce "label clutter," save money for manufacturers, and reflect the reality that the current rule has been rarely enforced in practice. FDA officials note that most supplement labels already fail to comply with the repeated-disclaimer requirement, and enforcement has been inconsistent for decades.

The Debate

Industry groups including the Council for Responsible Nutrition (CRN) have welcomed the proposal, arguing that excessive disclaimers confuse consumers and create unnecessary compliance burdens. However, public health advocates and consumer protection organizations warn that reducing the visibility of these disclaimers could lead consumers to overestimate the scientific evidence behind supplement health claims.

Separately, a new piece of legislation — the Dietary Supplement Regulatory Uniformity Act, introduced by Congressman Nick Langworthy — aims to establish consistent federal standards for supplement regulation, preventing a patchwork of potentially conflicting state-level rules. The bill has broad industry support but faces scrutiny from states that have enacted stricter supplement regulations.

Sources: Pharmacy Times — FDA May Relax Dietary Supplement Warning Label Rules | Nutraceutical Business Review — FDA Signals Possible Easing of Disclaimer Requirements | Nutritional Outlook — New Legislation Aims to Reaffirm FDA Authority Over Supplements

Explore our in-depth articles on the supplements, herbs, and health topics mentioned in today's news:

Trending Herbs & Adaptogens

Trending Superfoods & Mushrooms

Trending Minerals & Supplements

Trending Remedies & Protocols

Back to Table of Contents